| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 13 | 2025 | 704 | 1.960 |
Why?
|
| Hospitalization | 29 | 2026 | 1942 | 1.660 |
Why?
|
| Influenza Vaccines | 9 | 2025 | 501 | 1.650 |
Why?
|
| Intubation, Intratracheal | 11 | 2025 | 288 | 1.360 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 4 | 2025 | 188 | 1.070 |
Why?
|
| Vaccination | 15 | 2026 | 1044 | 1.030 |
Why?
|
| Respiratory Syncytial Virus Infections | 6 | 2026 | 385 | 0.990 |
Why?
|
| Laryngoscopes | 5 | 2025 | 71 | 0.920 |
Why?
|
| Critical Illness | 8 | 2024 | 616 | 0.800 |
Why?
|
| Heart Arrest | 5 | 2026 | 380 | 0.660 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 3 | 2025 | 80 | 0.650 |
Why?
|
| Cryptogenic Organizing Pneumonia | 1 | 2019 | 4 | 0.620 |
Why?
|
| Tracheal Neoplasms | 1 | 2019 | 22 | 0.610 |
Why?
|
| Bronchoscopy | 5 | 2019 | 179 | 0.600 |
Why?
|
| Pneumonia | 2 | 2022 | 344 | 0.590 |
Why?
|
| Laryngoscopy | 4 | 2025 | 158 | 0.580 |
Why?
|
| Esophageal Achalasia | 1 | 2019 | 48 | 0.570 |
Why?
|
| Aged | 38 | 2026 | 21263 | 0.540 |
Why?
|
| Adult | 44 | 2026 | 31710 | 0.510 |
Why?
|
| Respiration, Artificial | 5 | 2023 | 501 | 0.500 |
Why?
|
| Middle Aged | 39 | 2026 | 28897 | 0.500 |
Why?
|
| Thyroid Neoplasms | 1 | 2019 | 248 | 0.490 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 4 | 2025 | 126 | 0.490 |
Why?
|
| Pleurisy | 1 | 2015 | 6 | 0.470 |
Why?
|
| Humans | 79 | 2026 | 131781 | 0.460 |
Why?
|
| Obesity Hypoventilation Syndrome | 1 | 2015 | 4 | 0.460 |
Why?
|
| Time | 1 | 2015 | 96 | 0.460 |
Why?
|
| Hypothermia, Induced | 3 | 2026 | 175 | 0.450 |
Why?
|
| United States | 26 | 2026 | 11815 | 0.450 |
Why?
|
| Risk Assessment | 3 | 2015 | 3696 | 0.450 |
Why?
|
| Hemolysin Proteins | 1 | 2014 | 29 | 0.440 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2014 | 34 | 0.430 |
Why?
|
| Bacterial Toxins | 1 | 2014 | 171 | 0.410 |
Why?
|
| Sleep Apnea, Obstructive | 4 | 2019 | 236 | 0.390 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2019 | 2122 | 0.390 |
Why?
|
| Bronchopulmonary Sequestration | 1 | 2012 | 7 | 0.380 |
Why?
|
| Respiratory Syncytial Virus, Human | 3 | 2026 | 233 | 0.380 |
Why?
|
| Cardiopulmonary Resuscitation | 3 | 2026 | 340 | 0.370 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2014 | 234 | 0.370 |
Why?
|
| Case-Control Studies | 10 | 2026 | 3451 | 0.370 |
Why?
|
| Severity of Illness Index | 5 | 2026 | 3094 | 0.370 |
Why?
|
| Female | 41 | 2026 | 71221 | 0.360 |
Why?
|
| Hypoxia | 2 | 2024 | 246 | 0.350 |
Why?
|
| Pneumonectomy | 1 | 2012 | 151 | 0.340 |
Why?
|
| Staphylococcus aureus | 1 | 2014 | 485 | 0.340 |
Why?
|
| Intensive Care Units | 4 | 2025 | 517 | 0.330 |
Why?
|
| Male | 37 | 2026 | 65290 | 0.330 |
Why?
|
| Shock | 2 | 2022 | 96 | 0.320 |
Why?
|
| Sleep Apnea Syndromes | 3 | 2019 | 94 | 0.320 |
Why?
|
| Influenza B virus | 3 | 2025 | 102 | 0.320 |
Why?
|
| Noninvasive Ventilation | 2 | 2024 | 32 | 0.310 |
Why?
|
| Staphylococcal Infections | 1 | 2014 | 569 | 0.310 |
Why?
|
| Seasons | 4 | 2025 | 333 | 0.300 |
Why?
|
| Immunocompromised Host | 3 | 2022 | 313 | 0.280 |
Why?
|
| Aged, 80 and over | 10 | 2025 | 6916 | 0.270 |
Why?
|
| Immunization | 2 | 2025 | 307 | 0.260 |
Why?
|
| Influenza A virus | 2 | 2025 | 149 | 0.250 |
Why?
|
| Prospective Studies | 10 | 2026 | 6509 | 0.240 |
Why?
|
| Multimorbidity | 1 | 2026 | 25 | 0.240 |
Why?
|
| Legionnaires' Disease | 2 | 2017 | 8 | 0.240 |
Why?
|
| Coma | 1 | 2026 | 56 | 0.240 |
Why?
|
| Oseltamivir | 1 | 2025 | 19 | 0.230 |
Why?
|
| Emergency Service, Hospital | 4 | 2025 | 1217 | 0.210 |
Why?
|
| Bias | 1 | 2024 | 144 | 0.210 |
Why?
|
| Diagnosis, Differential | 4 | 2019 | 1912 | 0.200 |
Why?
|
| Polysomnography | 3 | 2019 | 155 | 0.200 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2024 | 90 | 0.200 |
Why?
|
| Emergency Medicine | 1 | 2025 | 172 | 0.200 |
Why?
|
| Hemoptysis | 2 | 2021 | 22 | 0.200 |
Why?
|
| Electronic Health Records | 3 | 2025 | 810 | 0.190 |
Why?
|
| RNA, Messenger | 6 | 2023 | 2570 | 0.190 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2003 | 102 | 0.190 |
Why?
|
| Adolescent | 11 | 2026 | 20994 | 0.190 |
Why?
|
| Paclitaxel | 1 | 2003 | 134 | 0.190 |
Why?
|
| Young Adult | 10 | 2026 | 10102 | 0.180 |
Why?
|
| Respiratory Paralysis | 1 | 2001 | 6 | 0.180 |
Why?
|
| Pulmonary Atelectasis | 1 | 2001 | 14 | 0.180 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2021 | 9 | 0.180 |
Why?
|
| Biopsy, Needle | 1 | 2002 | 216 | 0.180 |
Why?
|
| Hospital Mortality | 5 | 2025 | 1076 | 0.180 |
Why?
|
| Fever | 2 | 2026 | 312 | 0.180 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 40 | 0.170 |
Why?
|
| Fluid Therapy | 1 | 2022 | 145 | 0.170 |
Why?
|
| Sentinel Surveillance | 3 | 2025 | 26 | 0.170 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 119 | 0.170 |
Why?
|
| Vaccines, Synthetic | 4 | 2022 | 321 | 0.170 |
Why?
|
| Hypotension | 1 | 2022 | 185 | 0.160 |
Why?
|
| Aneurysm | 1 | 2021 | 68 | 0.160 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2001 | 122 | 0.160 |
Why?
|
| Respiratory Tract Infections | 1 | 2023 | 293 | 0.160 |
Why?
|
| Organ Transplantation | 1 | 2022 | 172 | 0.160 |
Why?
|
| Cystadenocarcinoma, Papillary | 1 | 2019 | 3 | 0.160 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2020 | 76 | 0.160 |
Why?
|
| Aneurysm, False | 1 | 2021 | 84 | 0.160 |
Why?
|
| Antiviral Agents | 1 | 2025 | 813 | 0.150 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 50 | 0.150 |
Why?
|
| Mediastinitis | 2 | 2017 | 16 | 0.150 |
Why?
|
| Azithromycin | 1 | 2019 | 45 | 0.150 |
Why?
|
| Preoperative Care | 1 | 2021 | 358 | 0.150 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2019 | 107 | 0.150 |
Why?
|
| Ovarian Neoplasms | 1 | 2003 | 455 | 0.140 |
Why?
|
| Cough | 1 | 2019 | 99 | 0.140 |
Why?
|
| Uterine Neoplasms | 1 | 2019 | 107 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 904 | 0.140 |
Why?
|
| Lung Diseases | 1 | 2002 | 401 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2025 | 1253 | 0.140 |
Why?
|
| Fatal Outcome | 1 | 2019 | 364 | 0.140 |
Why?
|
| Clinical Competence | 1 | 2025 | 1051 | 0.140 |
Why?
|
| Home Care Services | 1 | 2018 | 69 | 0.140 |
Why?
|
| Video Recording | 3 | 2025 | 208 | 0.140 |
Why?
|
| Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2017 | 30 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2003 | 1280 | 0.130 |
Why?
|
| Long-Term Care | 1 | 2017 | 70 | 0.130 |
Why?
|
| Paramyxoviridae Infections | 1 | 2017 | 49 | 0.130 |
Why?
|
| Diabetes Mellitus | 1 | 2024 | 891 | 0.120 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2023 | 650 | 0.120 |
Why?
|
| Patient Transfer | 1 | 2017 | 111 | 0.120 |
Why?
|
| Bacteremia | 1 | 2020 | 428 | 0.120 |
Why?
|
| Oxygen | 3 | 2024 | 553 | 0.120 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 143 | 0.120 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 1405 | 0.120 |
Why?
|
| Machine Learning | 1 | 2019 | 375 | 0.120 |
Why?
|
| Logistic Models | 2 | 2021 | 1838 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 4 | 2020 | 2576 | 0.110 |
Why?
|
| Respiratory Mechanics | 1 | 2015 | 80 | 0.110 |
Why?
|
| Legionella | 1 | 2014 | 9 | 0.110 |
Why?
|
| Community-Acquired Infections | 1 | 2017 | 254 | 0.110 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 251 | 0.110 |
Why?
|
| Respiratory Syncytial Viruses | 2 | 2025 | 153 | 0.100 |
Why?
|
| Immunization Schedule | 2 | 2025 | 111 | 0.100 |
Why?
|
| Patient Readmission | 1 | 2017 | 423 | 0.100 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 172 | 0.100 |
Why?
|
| Vaccines, Combined | 2 | 2022 | 39 | 0.100 |
Why?
|
| Lung | 3 | 2014 | 1566 | 0.100 |
Why?
|
| Algorithms | 1 | 2019 | 1685 | 0.100 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 1542 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2015 | 1235 | 0.090 |
Why?
|
| Disease Management | 1 | 2015 | 565 | 0.090 |
Why?
|
| Trachea | 2 | 2023 | 209 | 0.090 |
Why?
|
| Retrospective Studies | 8 | 2020 | 17667 | 0.090 |
Why?
|
| Self Report | 2 | 2025 | 562 | 0.090 |
Why?
|
| Prognosis | 3 | 2019 | 4953 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 1489 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 300 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 2299 | 0.080 |
Why?
|
| Heart Failure | 1 | 2023 | 2309 | 0.080 |
Why?
|
| Prevalence | 3 | 2026 | 2695 | 0.080 |
Why?
|
| RNA | 2 | 2023 | 531 | 0.080 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 1322 | 0.070 |
Why?
|
| Biopsy | 1 | 2012 | 1252 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2024 | 5122 | 0.070 |
Why?
|
| Treatment Outcome | 6 | 2025 | 12997 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2017 | 1215 | 0.060 |
Why?
|
| Sleep | 2 | 2019 | 373 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 5297 | 0.060 |
Why?
|
| Bayes Theorem | 1 | 2026 | 306 | 0.050 |
Why?
|
| Masks | 1 | 2024 | 38 | 0.050 |
Why?
|
| Risk Factors | 4 | 2026 | 10965 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2023 | 67 | 0.050 |
Why?
|
| Bronchial Diseases | 1 | 2003 | 11 | 0.050 |
Why?
|
| Platinum | 1 | 2003 | 13 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2006 | 229 | 0.050 |
Why?
|
| Time Factors | 2 | 2024 | 6279 | 0.050 |
Why?
|
| Mediastinoscopy | 1 | 2002 | 6 | 0.050 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2002 | 11 | 0.050 |
Why?
|
| Positive-Pressure Respiration | 1 | 2022 | 83 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2003 | 1522 | 0.050 |
Why?
|
| Embolism, Paradoxical | 1 | 2001 | 3 | 0.050 |
Why?
|
| Immunocompetence | 1 | 2022 | 31 | 0.050 |
Why?
|
| Heart Septum | 1 | 2001 | 45 | 0.040 |
Why?
|
| Viral Load | 1 | 2023 | 406 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 2022 | 135 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2003 | 178 | 0.040 |
Why?
|
| Hospitals | 1 | 2024 | 445 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 741 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2023 | 512 | 0.040 |
Why?
|
| Hypnotics and Sedatives | 1 | 2022 | 133 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 243 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2003 | 910 | 0.040 |
Why?
|
| Vancomycin Resistance | 1 | 2020 | 21 | 0.040 |
Why?
|
| Texas | 2 | 2021 | 3622 | 0.040 |
Why?
|
| Diaphragm | 1 | 2001 | 102 | 0.040 |
Why?
|
| Enterococcus | 1 | 2020 | 31 | 0.040 |
Why?
|
| Subclavian Artery | 1 | 2021 | 65 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2022 | 233 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2021 | 228 | 0.040 |
Why?
|
| Angiography | 1 | 2021 | 188 | 0.040 |
Why?
|
| Prostheses and Implants | 1 | 2001 | 148 | 0.040 |
Why?
|
| Nomograms | 1 | 2019 | 38 | 0.040 |
Why?
|
| Syndrome | 1 | 2022 | 1170 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2006 | 870 | 0.040 |
Why?
|
| Heart Atria | 1 | 2001 | 336 | 0.040 |
Why?
|
| Age Factors | 1 | 2025 | 2872 | 0.040 |
Why?
|
| Vancomycin | 1 | 2020 | 225 | 0.040 |
Why?
|
| Lung Transplantation | 1 | 2003 | 350 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2022 | 1638 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2003 | 824 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 1170 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2022 | 1235 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2001 | 256 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 580 | 0.030 |
Why?
|
| Tracheal Stenosis | 1 | 2017 | 31 | 0.030 |
Why?
|
| Cardiac Catheterization | 1 | 2001 | 635 | 0.030 |
Why?
|
| Legionella pneumophila | 1 | 2017 | 6 | 0.030 |
Why?
|
| Critical Care | 1 | 2002 | 680 | 0.030 |
Why?
|
| Metapneumovirus | 1 | 2017 | 53 | 0.030 |
Why?
|
| Length of Stay | 2 | 2017 | 1400 | 0.030 |
Why?
|
| Patient Safety | 1 | 2021 | 444 | 0.030 |
Why?
|
| Stents | 2 | 2017 | 778 | 0.030 |
Why?
|
| Drainage | 1 | 2017 | 253 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2017 | 175 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 3838 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1165 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 682 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 2221 | 0.030 |
Why?
|
| Streptococcus pneumoniae | 1 | 2017 | 389 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 1174 | 0.030 |
Why?
|
| Bronchoalveolar Lavage | 1 | 2014 | 22 | 0.030 |
Why?
|
| Incidence | 2 | 2017 | 3349 | 0.030 |
Why?
|
| Antigens, Bacterial | 1 | 2017 | 320 | 0.030 |
Why?
|
| Inflammation | 1 | 2022 | 1493 | 0.030 |
Why?
|
| Fiber Optic Technology | 1 | 2014 | 45 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 838 | 0.030 |
Why?
|
| Bronchi | 1 | 2014 | 102 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 544 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 324 | 0.030 |
Why?
|
| Animals | 1 | 2014 | 34402 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 1457 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2993 | 0.020 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 547 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2003 | 3134 | 0.020 |
Why?
|
| Ohio | 1 | 2006 | 88 | 0.020 |
Why?
|
| Sleep, REM | 1 | 2006 | 17 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2006 | 225 | 0.010 |
Why?
|
| Surgical Wound Infection | 1 | 2006 | 271 | 0.010 |
Why?
|
| Brain Diseases | 1 | 2006 | 305 | 0.010 |
Why?
|
| Perioperative Care | 1 | 2006 | 216 | 0.010 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2003 | 50 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2002 | 441 | 0.010 |
Why?
|
| Communicable Diseases | 1 | 2002 | 158 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2002 | 301 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2001 | 433 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 1304 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2002 | 667 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2001 | 1406 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 1260 | 0.010 |
Why?
|